Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2007 1
2009 1
2022 1
2023 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B, Burstein HJ, Davidson NE, Geyer CE Jr, Walley BA, Ingle JN, Coleman RE, Müller B, Le Du F, Loibl S, Winer EP, Ruepp B, Loi S, Colleoni M, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation). Francis PA, et al. J Clin Oncol. 2023 Mar 1;41(7):1370-1375. doi: 10.1200/JCO.22.01065. Epub 2022 Dec 9. J Clin Oncol. 2023. PMID: 36493334 Free PMC article. Clinical Trial.
The primary analysis compared disease-free survival (DFS) between tamoxifen plus OFS versus tamoxifen alone; exemestane plus OFS versus tamoxifen was a secondary objective. ...In conclusion, after 12 years, there remains a benefit from including OFS in adjuvant endo …
The primary analysis compared disease-free survival (DFS) between tamoxifen plus OFS versus tamoxifen alone; exemestane plus OFS v …
Analysis of consumer information brochures on osteoporosis prevention and treatment.
Meyer G, Steckelberg A, Mühlhauser I. Meyer G, et al. Ger Med Sci. 2007 Jan 11;5:Doc01. Ger Med Sci. 2007. PMID: 19675709 Free PMC article.
Quality of brochures did not differ between providers. Only 1 brochure presented lifetime risk estimate; 4 mentioned natural course of osteoporosis. A balanced report on benefit versus lack of benefit was presented in 2 brochures and on benefit versus adverse …
Quality of brochures did not differ between providers. Only 1 brochure presented lifetime risk estimate; 4 mentioned natural course o …
Relationships among breast cancer perceived absolute risk, comparative risk, and worries.
Lipkus IM, Kuchibhatla M, McBride CM, Bosworth HB, Pollak KI, Siegler IC, Rimer BK. Lipkus IM, et al. Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):973-5. Cancer Epidemiol Biomarkers Prev. 2000. PMID: 11008917 Clinical Trial.
This study examines the extent to which women's worries about breast cancer correlate with perceptions of both absolute (assessment of own) and comparative (self versus other) 10-year and lifetime risks. ...Our data suggest that they should give careful consideratio …
This study examines the extent to which women's worries about breast cancer correlate with perceptions of both absolute (assessment o …
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
Burton JM, O'Connor PW, Hohol M, Beyene J. Burton JM, et al. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006921. doi: 10.1002/14651858.CD006921.pub2. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2012 Dec 12;12:CD006921. doi: 10.1002/14651858.CD006921.pub3. PMID: 19588409 Updated.
OBJECTIVES: The primary objective was to compare efficacy of oral versus intravenous steroids for MS relapses <= 6 weeks. Secondary comparisons included subsequent relapse rate, disability, ambulation, hospitalization, immunological markers, radiological markers, and qu …
OBJECTIVES: The primary objective was to compare efficacy of oral versus intravenous steroids for MS relapses <= 6 weeks. Secondar …